Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025036 | 0.88 | NR3C2 (0.48) | PTGS2NR3C1BRD4NR3C2HPGD | |
| SCHEMBL12081775 | 0.88 | CYP17A1 (0.45) | METNR3C1CYP17A1BRD4NR3C2 | |
| SCHEMBL12081721 | 0.88 | KIF11 (0.39) | KIF11PTGS2NR3C1CYP17A1BRD4 | |
| SCHEMBL3022634 | 0.87 | CYP17A1 (0.45) | KIF11PTGS2IKBKBCHUKCYP17A1 | |
| SCHEMBL3017436 | 0.86 | CYP17A1 (0.44) | KIF11PTGS2NR3C1CYP17A1BRD4 | |
| SCHEMBL12081699 | 0.86 | GLO1 (0.40) | KIF11GLO1NR3C2ADRA1DADRA1A | |
| SCHEMBL3026326 | 0.86 | CYP17A1 (0.39) | KIF11CYP17A1BRD4NR3C2ADRA1D | |
| SCHEMBL3011521 | 0.85 | NR3C2 (0.39) | KIF11CYP17A1BRD4NR3C2ADRA1D | |
| SCHEMBL12081663 | 0.85 | PGR (0.47) | NR3C1NR3C2ADRA1DADRA1A | |
| SCHEMBL12081678 | 0.85 | KIF11 (0.52) | KIF11NR3C1CYP17A1NR3C2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | claimed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | claimed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | claimed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | claimed |
| US-9730948-B2 | Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-08-15 | — | — | US | disclosed |
| WO-2017064121-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-04-20 | — | — | WO | disclosed |
| US-20160136183-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | Universite De Paris (FR) | 2016-05-19 | — | — | US | disclosed |
| WO-2016005424-A1 | METHODS FOR ASSESSING MINERALOCORTICOID RECEPTOR ACTIVATION IN ADIPOSE TISSUE OF A SUBJECT AND TREATING METABOLIC SYNDROME | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-01-14 | — | — | WO | disclosed |
| WO-2014202744-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2014-12-24 | — | — | WO | disclosed |
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | KIF11 2363/4885PTGS2 1372/4885MET 244/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | KIF11 2908/4885PTGS2 1072/4885MET 203/4885 |
| US-20160136183-A1 | PHARMACEUTICAL COMPOSITIONS FOR PREVENTING GLUCOCORTICOID-INDUCED CORNEAL OR SKIN THINNING | NR3C1, NR3C2, MC2R | KIF11 3277/4885PTGS2 41/4885MET 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.